Astellas is focused on maximizing the value of the main products that will drive growth in each region, such as XTANDI and Betanis/Myrbetriq/BETMIGA.

Prostate Cancer Treatment

XTANDI for the treatment of prostate cancer is an androgen receptor signaling inhibitor.

Since being launched in the U.S. in 2012, XTANDI is now available around the world, including in Europe, Japan and Asia. Since the launch, it has obtained additional indications for the earlier stages of prostate cancer and has been contributed to the treatment of many patients. With a strong presence in the urological field and leveraging abundant data based on accumulated clinical experience since its launch, Astellas aims for further penetration for the indications it has already received.

Acute Myeloid Leukemia (AML) Treatment

XOSPATA is a FLT3 inhibitor for adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) with a FLT3 mutation-positive.

It obtained approval for the indication of relapsed or refractory AML with FLT3 mutation-positive in Japan in September 2018 and in the U.S. in November. It was launched in both countries in December 2018. Astellas also filed an application for approval in Europe in February 2019. The launch of XOSPATA contributes to treating AML by providing another treatment option for healthcare professionals involved in treating AML.

Overactive Bladder (OAB) Treatment

Betanis/Myrbetriq/BETMIGA for the treatment of OAB is a beta-3 adrenergic receptor agonist. It improves various symptoms associated with OAB, such as urgency, urinary frequency, and urge urinary incontinence, by a new mode of action different from the anticholinergic drugs used in standard treatment.

Since the first launch in Japan in 2011 under the brand name of Betanis, the product is now launched as Myrbetriq in the Americas, and BETMIGA in Europe and Asia & Oceania. Astellas aims to maximize the product value by ensuring that more physicians understand the balance between efficacy and tolerability, the feature of this product.

Prograf and Advagraf/Graceptor/ASTAGRAF

Prograf and Advagraf/Graceptor/ASTAGRAF are an immunosuppressant used to suppress organ transplant rejection. Although the patent for this drug has already expired in major countries, it continues being used in transplants area globally as well as contributing to treatment for autoimmune diseases such as rheumatoid arthritis and ulcerative colitis in Japan.


OAB treatment:                                                   Vesicare
Prostate cancer treatment:                              Eligard
Benign prostatic hyperplasia treatment:    Harnal/Omnic
Antifungal agent:                                                Funguard/MYCAMINE


Please refer to the Supplementary Documents (pdf) of the Business Results about sales of major products in each region, including the products above.